Gaudreau, P., Lee, J. J., Heymach, J. V., & Gibbons, D. L. (2020). Phase I/II Trial of Immunotherapy with Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early trial report. Clin Lung Cancer.
Chicago Style CitationGaudreau, Pierre-Olivier, J. Jack Lee, John V. Heymach, i Don L. Gibbons. "Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report." Clin Lung Cancer 2020.
Cita MLAGaudreau, Pierre-Olivier, J. Jack Lee, John V. Heymach, i Don L. Gibbons. "Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report." Clin Lung Cancer 2020.